 |
|
|
|
|
|
Cell>Point adds Dr. Eric
Kurzweil to Board of Advisors
9/11/2008 |
|
|
|
CENTENNIAL, Colo., September 11,
2008 Cell>Point is pleased to
announce that Eric Kurzweil,
M.D., MBA has joined our Board
of Advisors. Dr. Kurzweil is
currently President of the Rocky
Mountain Region of Pediatrix.
Pediatrix, a $2.63 billion
market cap company listed on the
NYSE:PDX which includes more
than 900 physicians nationwide.
Dr. Kurzweil received his
undergraduate degree from
Harvard University and his
medical degree from the
University of Miami School of
Medicine. Dr. Kurzweil earned
his masters degree of business
administration from the
University of Colorado. |
|
|
|
|
|
|
|
Cell>Point establishes European
subsidiary
7|1|08 |
|
|
|
CENTENNIAL, Colo., July 1,
2008 -
Cell>Point announced today
that it has established a subsidiary in the Netherlands,
Cell>Point Netherlands BV. Cell>Point plans to expand its
operation in Europe including financial partners and European
clinical trial sites for its Phase III clinical trials in
99mTc-EC-G. |
|
|
|
|
|
|
|
Cell>Point technology featured
on Fox National News
4|18|08 |
|
|
|
CENTENNIAL, Colo., April 18,
2008 -
Cell>Point announced today
that EC Technology was featured
on Fox National News.
click
(video) |
|
|
|
|
|
|
|
Cell>Point featured on NBC 9
News 4|2|08 |
|
|
|
CENTENNIAL, Colo., April 2, 2008 - Cell>Point announced today that it was
featured on NBC 9 News Denver. To see feature please
click
(video) |
|
|
|
|
|
|
|
|
|
Cell>Point to present at
Wachovia 2008 Healthcare
Conference 1|25|08 |
|
|
CENTENNIAL, Colo., January 25,
2008 Cell>Point, L.L.C. today
announced that it will present
at the Wachovia 2008 Healthcare
Conference, which will be held
January 29-31, 2008, at The
Langham Hotel in Boston, Mass.
Cell>Point will present
Thursday, January 31 at 1:00 pm
(Eastern Time) in the Palmer
Room.
|
|
|
|
|
|
|
|
Diagnostic Imaging April 2007
Article 4|18|07 |
|
|
Cell>Point was featured in the
Diagnostic Imaging April 2007
issue "Small biopharm company
hatches plan to unseat FDG" according
to Terry Colip, Managing Partner
of Cell>Point. To view article
go to
www.diagnosticimaging.com,
April 2007 issue.
|
|
|
|
|
|
|
|
CellPoint has cancer
detection in its sights
1|27|07 |
|
|
|
CellPoint
has cancer detection in its
sights
By Will Shanley
Denver Post Staff Writer< ... full
article
|
|
|
|
|
|
|
|
Dr. F. David Rollo joins
Cell>Point as President
9|12|06 |
|
|
|
CENTENNIAL,
Colo.,
September 12, 2006 Terry
Colip, Managing
Partner atCell>Point today
announced F. Dav ... full
article |
|
|
|
|
|
|
|
Cell>Point featured on CNBC
9|7|06
|
|
|
|
CENTENNIAL, Colo., September 7,
2006 - Cell>Point will
befeatured on CNBC September 13,
2006. The video from CNBC will
be available from our homepage
on September 22, 2006. ... full
article |
|
|
|
|
|
|
|
Cell>Point expands clinical
trial for Imaging Myocardial
Viability 6|1|06 |
|
|
|
CENTENNIAL, Colo., June 1, 2006
-Cell>Point
today announced it plans to
start a Phase II clinical trial
to evaluate the effectiveness of
its 99mTc-EC-DG
(Technetium-99m-Ethylenedicys-teine-Deoxyglucose)
in diagnosing ... full
article |
|
|
|
|
|
|
|
Cell>Point named Biotech
Rising Star of the Year
11|8|05 |
|
|
|
ENGLEWOOD, Colorado - November,
8, 2005 - Cell>Point was named
Biotech "Rising Star of theYear"
by the Colorado BioScience
Association according to Terry
Colip, Managing Partner of
Cell>Point. ... full
article |
|
|
|
|
|
|
|
Cell>Point acquires
Oligosaccharide Conjugate
License 6|3|05 |
|
|
|
HOUSTON, Texas - June 3, 2005 -
Cell>Point obtained the
worldwide patent and technology
license to Oligosaccharide
Conjugates for Dual Imaging and
Radio/Chemotherapy developed at
The University of Texas M. D.
Anderson Cancer Center. This
novel technology is facilitating
the development of combination
modality diagnostic imaging
agents and new combination
radio/chemotherapeutic agents
for use in oncology, cardiology,
neuroendocrinology and
infectious diseases. The imaging
ag ... full
article |
|
|
|
|
|
|
|
Cell>Point featured in Aunt
Minnie 5|20|05 |
|
|
|
ENGLEWOOD,Colorado-May20,2005-Cell>Point
was featured in the following
Aunt Minnie article
BiotechfirmCell>Point sees
promise for oncology SPECT
1/20/2005
By:
Kate Madden Yee
Since PET imaging was
introduced in the 1990s, its
advocates have slowly but surely
established a place for the
technology, so much so that PET
is now considered by many to be
the best modality for functional
oncology imaging.
PET' ... full
article |
|
|
|
|
|
|
|
EC Technology featured in
Basel, Switzerland 4|21|05
|
|
|
|
HOUSTON, Texas - April 21, 2005
- Cell>Point announced today
that David J. Yang, Ph.D. will
present our EC Technology at the
Joint Meeting of the Austrian,
German, and Swiss Societies of
Nuclear Medicine to be held in
Basel, Switzerland (April 27-30,
2005). ... full
article |
|
|
|
|
|
|
|
Cell>Point to present at 30th
Annual Deutsche Bank Health Care
Conference 4|20|05 |
|
|
|
ENGLEWOOD, Colorado - April 20,
2005 -Cell>Point will be a
presenting company at the 30th
Annual Deutsche Bank Health Care
Conference to be held in
Baltimore, May 2-4, 2005. The
webcast can be viewed at
http://www.corporate-ir.net/ireye/confRegistration.zhtml?ticker=W189917&item_id=ew,1055963,1,189917,438136,524157 ... full
article |
|
|
|
|
|
|
|
Cell>Point acquires N4
Technology License 3|1|05
|
|
|
|
HOUSTON, Texas - March 1, 2005 -
Cell>Point obtained the
worldwide patent and technology
license on February 14, 2005 to
tatraazacyclopentadecane (N4)
technology developed at The
University of Texas M.D.
Anderson Cancer Center. N4
Technology will form the
foundation for the development
of Positron Emission Tomography
imaging agents using generator
based isotopes as well as
compounds for imaging and
treating neuroendocrine tumors
and certain diseases affecting
the centra ... full
article |
|
|
|
|
|
|
|
Cell>Point to Present at Rice
Forum 2|22|05 |
|
|
|
HOUSTON, Texas - February 22,
2005 - Cell>Point has been
selected to be a presenting
company at the 4th Annual Rice
Alliance Life Science Technology
Venture Forum on March 11, 2005
at Rice University. Greg R.
Colip, President of the company,
will present an overview of the
company and its technology
platforms. The Rice Alliance
Forum brings together
biotechnology companies, angel
investors, venture capital firms
and law firms who specialize in
the area of biotechnology. The
Forum ... full
article |
|
|
|
|
|
|
|
Dr. Saad Zakko joins
Scientific Advisory Board
9|8|04 |
|
|
|
HOUSTON,
Texas - September 1, 2004 �Cell>Point is pleased to
announce that Dr. Saad Zakko has
joined our Scientific Advisory
Board. Dr. Zakko has been
Consultant to the Department of
Nuclear Medicine at
Dubai
Hospitalfull article |
|
|
|
|
|
|
|
Cell>Point completes clinical
pilot study on 99mTc-EC-Annexin
V 4|1|04 |
|
|
|
HOUSTON,Texas-April1,2004
-Cell>Point L.L.C. completes
clinical pilot study on 99mTc-EC-Annexin
V at The University of Texas
M.D. Anderson Cancer Center. The
study evaluated the use of 99m
Tc-EC-Annexin V to assess tumor
apoptosis (programmed cell
death) in patients with primary
breast cancer and to detect
an ... full
article |
|
|
|
|
|
|
|
Royal Philips Electronics
collaborates with Cell>Point
9|29|03 |
|
|
|
HOUSTON, Texas - September 29,
2003 - Royal Philips Electronics
(NYSE: PHG, AEX: PHI) announced
today that it will collaborate
with Cell>Point, L.L.C, a
biotechnology company based in
Englewood, Colo., to optimize
Cell>Point's novel diagnostic
imaging agent on Philips'
SKYLight า gantry-free gamma
camera. The companies will share
clinical trial costs to develop
the best imaging techniques for
improved clinical information
and accuracy of diagnoses. The
joint goal is to develop ... full
article |
|
|
|
|
|
|
|
Cell>Point L.L.C. Completes
Exclusive License Negotiations
for Second Technology Platform �
In Situ Hydrogel 7|1|03
|
|
|
|
In July 2003, the company
completed exclusive license
negotiations with M.D. Anderson
for a second technology
platform, In Situ Hydrogel,
which will be used for local
regional chemotherapy and
radiotherapy. In comparison with
other hydrogel technologies, In
Situ Hydrogel is the only
hydrogel formulation capable of
delivering a high yield load of
a therapeutic radionuclide like
188Re directly to the
tumor site without leakage into
surrounding tissue. The In Situ
Hydrog ... full
article |
|
|
|
|
|
|
|
Cell>Point L.L.C. Preparing
to Conduct Studies 10|1|02
|
|
|
|
HOUSTON, Texas - October 2002
- Cell>Point L.L.C. is preparing
to commence clinical biokinetic
and biodistribution studies at
The University of Texas M.D.
Anderson Cancer Center on
99mTc-EC-Metronidazole,
99mTc-EC-Annexin V
and 99mTc-EC-Cox-2.
If results from the studies are
as expected,Cell>Point will
prepare and submit IND
applications with the FDA for
the three "kit" compounds.
99mTc-EC-Metronidazole
wi ... full
article |
|
|
|
|
|
|
|
Cell>Point Receives Approval
of its Investigations New Drug
Application for 99mTc-EC-Deoxyglucose
6|1|02 |
|
|
|
HOUSTON, Texas - June 2002 -
Cell>Point L.L.C. (Englewood,
CO) received approval of its
Investigational New Drug
Application for 99mTc-EC-Deoxyglucose
(known in the clinical trial as
"CP6262") from the FDA on June
26. The Phase I clinical trial
will be conducted at The
University of Texas M.D.
Anderson Cancer Center in
Houston, Texas. CP6262 is a
technetium-99m labeled molecular
imaging agent that will be used
as a diagnostic tool in oncology
to identify active tumor ... full
article |
|
|
|
|
|
|
|
Cell>Point, L.L.C. Executes
Exclusive Worldwide Patent and
Technology License Agreement for
ethylenedicysteine 7|1|01
|
|
|
|
HOUSTON, Texas - July 2001 -
Cell>Point, L.L.C. executed an
exclusive worldwide Patent and
Technology License Agreement
with The University of Texas
M.D. Anderson Cancer Center for
ethylenedicysteine ("EC") drug
conjugate technology which
functions as a chemical bridge
linking diagnostic radio-tracers
or therapeutic radionuclides to
ligand disease target seekers or
novel FDA approved drugs.
Technetium-99m-EC-deoxyglucose
("99mTc-EC-DG") will
be the first of m ... full
article |
|
|
|
|
|
|
|
|
|
|
r & d
